Ferric Carboxymaltose vs Iron Isomaltoside in treating Iron-Deficiency Anemia
Iron-deficiency anemia is today’s global health issue. Iron isomaltoside 1000 now known as ferric derisomaltose and ferric carboxymaltose
are intravenous iron formulations developed to treat those who are suffering
from iron-deficiency anemia, especially in patients who do not tolerate or fail
to respond to oral iron. Risks of hypophosphatemia following iron
replacement with iron isomaltoside 1000 vs ferric carboxymaltose:
There are randomized trials twice on 245 patients in total. In trial A: number = 123 & in trial B:
number = 122 suffering from iron-deficiency anemia (either intolerant to or
unresponsive to oral iron). It was found that the incidence of hypophosphatemia
with iron-isomaltoside, when compared with ferric carboxymaltose was 7.9% vs 75%
in the trial A and 8.1% vs 73.7% in trial B for over 35 days.
The differences were statistically important.
The Conclusion:
We can thus say that iron isomaltoside when compared with ferric carboxymaltose
resulted in lower incidence of hypophosphatemia. However, further research is
required to determine the findings.
Comments
Post a Comment